Tag: immunomodulator market research

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Immunomodulator Market from 2024 to 2033?
The immunomodulator market has experienced strong growth recently. It will rise from $204.37 billion in 2023 to $219.94 billion in 2024, reflecting a CAGR of 7.6%. The growth is driven by healthcare infrastructure development, increased patient awareness, an aging population, a rise in autoimmune diseases, and the introduction of biologic drugs.

The immunomodulator market is projected to grow significantly, reaching $297.15 billion by 2028 at a CAGR of 7.8%. Growth factors include patient preferences for non-invasive treatments, regulatory support, health insurance coverage, and government healthcare spending. Major trends involve advancements in biotechnology, the research pipeline for immunomodulatory drugs, and a shift toward personalized medicine.

Claim Your Free Sample of the Global Immunomodulator Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15591&type=smp

What Key Factors Are Fueling the Growth of the Immunomodulator Market?
The increase in chronic diseases is projected to boost the growth of the immunomodulator market. Chronic diseases are long-term medical conditions that develop slowly and can last for years or even a lifetime. Their rising prevalence is linked to factors such as an aging population, lifestyle choices, genetic factors, and healthcare accessibility. Immunomodulators offer important therapeutic options for managing these diseases by influencing immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom management. For example, in September 2023, the World Health Organization reported 41 million deaths globally attributed to non-communicable diseases (NCDs), accounting for 74% of total deaths each year. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Thus, the rise in chronic diseases is propelling the growth of the immunomodulator market.

What Are the Major Segments of the Immunomodulator Market?
1) By Product Type: Immunosuppressants; Immunostimulants; Other Product Types
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Oncology; Respiratory; Human Immunodeficiency Virus; Other Applications
4) By End-User: Hospitals; Clinics; Other End Users

What New Trends Are Transforming the Immunomodulator Market?
Major firms in the immunomodulator market are developing non-immunosuppressive products to meet the demand for targeted immune modulation. In February 2024, Nuvig Therapeutics, Inc., a US biotech company, initiated early-stage trials for NVG-2089, a next-generation immune modulator aimed at treating inflammatory myopathies and autoimmune diseases.

Order Now for Fast Delivery of Your Immunomodulator Market Report!
https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Which Regions Are Driving Growth in the Immunomodulator Market?
North America was the largest region in the immunomodulator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Immunomodulator Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the immunomodulator market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Immunomodulator Market Include

1. Immunomodulator Market Executive Summary
2. Immunomodulator Market Segments
3. Immunomodulator Market Size And Template Market Growth Rate
4.  Key Immunomodulator Market Trends
5. Major Immunomodulator Market Drivers
……
25. Key Mergers And Acquisitions In The Immunomodulator Market
26. Top Immunomodulator Companies
27. Immunomodulator Market Opportunities And Strategies
28. Immunomodulator Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Intravenous Immunoglobulin Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunosuppressants Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

Immuno-Oncology Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Strong Market Expansion from 2023 to 2024

• The immunomodulator market has witnessed significant growth, expanding from $204.37 billion in 2023 to $219.94 billion in 2024.
• The market is growing at a compound annual growth rate (CAGR) of 7.6%.
• Key drivers of growth include the development of healthcare infrastructure, increased patient awareness, and a growing aging population.
• The rising incidence of autoimmune diseases and the introduction of biologic drugs have also played a pivotal role.

Future Growth Projections: 2024 to 2028

• The market size is expected to grow further, reaching $297.15 billion by 2028 at a CAGR of 7.8%.
• Growth factors include an increasing patient preference for non-invasive treatments, regulatory approvals, and comprehensive health insurance coverage.
• The expansion of immunomodulatory drugs and rising government healthcare expenditures will also contribute to market growth.
• Emerging trends such as advancements in biotechnology, personalized medicine, and immuno-oncology are set to shape the future of the market.

View More On The Immunomodulator Market Report 2024 – https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Chronic Diseases Driving Market Expansion

• The rise in chronic diseases, which are long-lasting and persist for extended periods, is a significant growth driver for the immunomodulator market.
• Factors contributing to the prevalence of chronic diseases include aging populations, lifestyle choices, and genetic predispositions.
• Immunomodulators offer valuable therapeutic options, including immune response modulation, inflammation reduction, and symptom control.
• According to the World Health Organization, 74% of global deaths are due to non-communicable diseases (NCDs) or chronic diseases.
• Specific causes of death include cardiovascular diseases (17.9 million), cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).

Key Players in the Immunomodulator Market

• Major companies in the market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, and Novartis AG.
• Other significant players are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and Gilead Sciences Inc.

Innovation in Non-Immunosuppressive Immunomodulators

• Companies are increasingly focused on developing non-immunosuppressive products that provide targeted immune modulation without compromising overall immune function.
• In February 2024, Nuvig Therapeutics, Inc. began early-stage clinical trials for NVG-2089, a next-generation immune modulator.
• NVG-2089 targets type II Fc receptors, reducing autoimmune dysregulation and showing promise in treating inflammatory myopathies and severe dermatologic autoimmune diseases.
• The FDA has granted fast-track designation for NVG-2089’s development in bullous pemphigoid.

Strategic Acquisitions Driving Market Growth

• In February 2022, Equillium, Inc. acquired Bioniz Therapeutics Inc., significantly expanding its immunology pipeline.
• The acquisition brought two first-in-class clinical-stage assets and a proprietary product discovery platform to Equillium’s portfolio.
• Bioniz Therapeutics focuses on cytokine-targeted medicines for immuno-inflammatory disorders and cancer, contributing to the broader immunomodulator market.

Market Segmentation and Regional Insights

• The immunomodulator market is segmented by product type into immunosuppressants, immunostimulants, and other product types.
• Distribution channels include hospital pharmacy, online pharmacy, retail pharmacy, and other channels.
• The market applications range across oncology, respiratory conditions, human immunodeficiency virus (HIV), and other areas.
• North America led the market in 2023, while Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Request A Sample Of The Global Immunomodulator Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15591&type=smp